These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 16603585

  • 1. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
    Alfonso-Pérez M, López-Giral S, Quintana NE, Loscertales J, Martín-Jiménez P, Muñoz C.
    J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
    [Abstract] [Full Text] [Related]

  • 2. PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.
    Hu C, Xiong J, Zhang L, Huang B, Zhang Q, Li Q, Yang M, Wu Y, Wu Q, Shen Q, Gao Q, Zhang K, Sun Z, Liu J, Jin Y, Tan J.
    Cell Mol Immunol; 2004 Aug; 1(4):280-94. PubMed ID: 16225771
    [Abstract] [Full Text] [Related]

  • 3. Effect of alemtuzumab on neoplastic B cells.
    Golay J, Manganini M, Rambaldi A, Introna M.
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [Abstract] [Full Text] [Related]

  • 4. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.
    López-Giral S, Quintana NE, Cabrerizo M, Alfonso-Pérez M, Sala-Valdés M, De Soria VG, Fernández-Rañada JM, Fernández-Ruiz E, Muñoz C.
    J Leukoc Biol; 2004 Aug; 76(2):462-71. PubMed ID: 15155773
    [Abstract] [Full Text] [Related]

  • 5. Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines.
    Robertson MJ, Williams BT, Christopherson K, Brahmi Z, Hromas R.
    Cell Immunol; 2000 Jan 10; 199(1):8-14. PubMed ID: 10675270
    [Abstract] [Full Text] [Related]

  • 6. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
    de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H.
    Br J Haematol; 2008 Mar 10; 140(6):635-43. PubMed ID: 18302712
    [Abstract] [Full Text] [Related]

  • 7. Neuroblastoma impairs chemokine-mediated dendritic cell migration in vitro.
    Walker SR, Ogagan PD, DeAlmeida D, Aboka AM, Barksdale EM.
    J Pediatr Surg; 2006 Jan 10; 41(1):260-5. PubMed ID: 16410144
    [Abstract] [Full Text] [Related]

  • 8. CCR7-mediated c-Jun N-terminal kinase activation regulates cell migration in mature dendritic cells.
    Iijima N, Yanagawa Y, Clingan JM, Onoé K.
    Int Immunol; 2005 Sep 10; 17(9):1201-12. PubMed ID: 16027136
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J.
    J Immunol; 2011 Mar 15; 186(6):3762-9. PubMed ID: 21296976
    [Abstract] [Full Text] [Related]

  • 11. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW.
    Br J Haematol; 2013 Oct 15; 163(2):182-93. PubMed ID: 23927424
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC.
    Br J Haematol; 2007 Dec 15; 139(5):837-44. PubMed ID: 17949452
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.
    J Immunol; 2009 Oct 01; 183(7):4782-91. PubMed ID: 19748990
    [Abstract] [Full Text] [Related]

  • 17. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 18. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.
    Lung Cancer; 2009 Jan 01; 63(1):23-31. PubMed ID: 18524412
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL, Merle-Beral H, Vieillard V.
    Leukemia; 2011 Jan 01; 25(1):101-9. PubMed ID: 20975664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.